Amgen Tracks Long-Term Romosozumab Safety in Children: What Investors Should Know

Amgen Inc (AMGN) announced an update on their ongoing clinical study.

This Amgen Inc. (AMGN) study, titled “Multicenter, Safety Follow-up Study to Assess Safety of Prior Treatment With Romosozumab in Children and Adolescents With Osteogenesis Imperfecta,” tracks long-term safety in young patients who previously joined trial 20200105. It focuses on how prior romosozumab exposure affects overall safety while patients continue standard care for brittle bone disease.

The trial does not give romosozumab again. Instead, participants receive standard bone health support, mainly calcium and vitamin D supplements, guided by local practice. The goal is to spot any delayed safety issues while maintaining routine care that helps strengthen bones and reduce fracture risk.

This is an interventional Phase 3 follow-up using a single-group design with no randomization. All enrolled patients are observed in the same way, and there is no masking, meaning doctors and families know the treatment plan, as the main purpose is supportive care and ongoing safety tracking rather than testing new dosing.

The study was first submitted on 5 January 2026, marking the formal start of regulatory review and site setup. The latest update was filed on 22 April 2026, which signals that the design and status have been recently refreshed and that recruitment is actively underway.

For investors, this update underscores Amgen’s push to build a safety record for romosozumab in a rare pediatric setting, which could support label expansion over time. While revenue impact near term is limited, strong long-term safety data could enhance the franchise’s durability versus competitors in bone health, improving sentiment around AMGN’s risk profile.

The study is currently ongoing and has been recently updated, with more details available on the ClinicalTrials portal.

To learn more about AMGN’s potential, visit the Amgen Inc drug pipeline page.